NCT05435053 (CHECKPOINT) is a Phase 2 clinical trial of Nivolumab in Pancreas Cancer, sponsored by Ismail Gögenur.

Who is sponsoring NCT05435053?

NCT05435053 is sponsored by Ismail Gögenur.

What drugs are being tested in NCT05435053?

Interventions in NCT05435053: Nivolumab, Irreversible electroporation (IRE).

What condition does NCT05435053 study?

NCT05435053 studies Pancreas Cancer.

Is NCT05435053 still recruiting?

NCT05435053 is currently terminated. Last updated 15 September 2023.

Last reviewed 2023-09-15 · How we verify

NCT05435053: CHECKPOINT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

Terminated Phase 2 Last updated 15 September 2023

What this trial tests

Phase 2 trial testing Nivolumab in Pancreas Cancer in 9 participants. Terminated before completion.

Timeline

8 September 2022

Primary endpoint
30 August 2023

30 August 2023

Quick facts

Lead sponsor	Ismail Gögenur
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	8 September 2022
Primary completion	30 August 2023
Estimated completion	30 August 2023
Sites	1 location across Denmark

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →
Irreversible electroporation (IRE)

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →

Sponsor

Ismail Gögenur — full company profile →

Who can join

Adults 18 to 100, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial investigates the safety and efficacy of irreversible electroporation in combination with checkpoint inhibition in patients with metastatic pancreatic cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

<i>In-situ</i> tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy.
Kim NJ, Yoon JH, Tuomi AC, Lee J, et al · · 2023 · cited 6× · PMID 36969248 · DOI 10.3389/fimmu.2023.1118845
B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy.
Chen X, Li J, Chen Y, Que Z, et al · · 2022 · cited 3× · PMID 36499340 · DOI 10.3390/ijms232315005
Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.
Li M, Zhou R, Qiu Y, Peng Y, et al · · 2025 · cited 1× · PMID 40642496 · DOI 10.21147/j.issn.1000-9604.2025.03.13

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other Ismail Gögenur trials

Trials by the same sponsor.

NCT07409844 — Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer · Phase 2 · not yet recruiting
NCT05740969 — Gene and Protein Expression Profiles After Treatment of Actinic Keratoses · Phase 2 · unknown
NCT05609656 — Electroporation and Immunotherapy in Metastatic Colorectal Cancer · Phase 2 · terminated
NCT05740137 — Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy · NA · completed
NCT05754229 — Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05435053 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ismail Gögenur
Last refreshed: 15 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05435053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing